Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14969753 | 0.66 | BLM (0.33) | P2RX7KDM4EALDH1A1GAAMAPT | |
| SCHEMBL13845478 | 0.58 | — | — | |
| SCHEMBL6435402 | 0.58 | — | — | |
| SCHEMBL25780920 | 0.56 | KDM4E (0.34) | P2RX7KDM4EALDH1A1GAAMAPT | |
| SCHEMBL13067938 | 0.55 | FUCA1 (0.31) | — | |
| SCHEMBL5061904 | 0.54 | — | — | |
| SCHEMBL23447866 | 0.54 | ALDH1A1 (0.31) | KDM4EALDH1A1MAPTCA1CA2 | |
| SCHEMBL28723691 | 0.52 | KDM4E (0.44) | P2RX7KDM4EALDH1A1GAAMAPT | |
| SCHEMBL343630 | 0.52 | MPO (0.80) | KDM4EALDH1A1GAAMAPTCA1 | |
| SCHEMBL1893743 | 0.52 | KDM4E (0.68) | P2RX7KDM4EALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085550-B2 | Ligands for estrogen related receptors and methods for synthesis of said ligands | CITY OF HOPE (US) | 2015-07-21 | — | — | US | disclosed |
| US-20130131340-A1 | LIGANDS FOR ESTROGEN RELATED RECEPTORS AND METHODS FOR SYNTHESIS OF SAID LIGANDS | FORMAN BARRY (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131340-A1 | LIGANDS FOR ESTROGEN RELATED RECEPTORS AND METHODS FOR SYNTHESIS OF SAID LIGANDS | ESRRA, ESRRB, ESR2 | P2RX7 3044/4885KDM4E 773/4885ALDH1A1 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.